DNA methylation and the Epstein-Barr virus

Seminars in Cancer Biology

Volumn 9, Issue 5, 1999, Pages 369-375

  Ambinder, Richard F ^a   Robertson, Keith D ^b   Tao, Qian ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Burkitts lymphoma; EBNA; Epstein Barr virus; Hodgkin's disease; Methylation; Nasopharyngeal carcinoma

Indexed keywords

DNA; VIRUS DNA;

ARTICLE; CPG ISLAND; DNA METHYLATION; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; NONHUMAN; PROMOTER REGION; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS INFECTION;

EID: 0032760250     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1999.0137     Document Type: Article

References (62)

1. Rickinson AB, Kieff E. Epstein-Barr virus, Fields B N, Knipe D M, Howley P M,. Fields Virology. 1996;2397-2446 Lippincott Raven Publishers, Philadelphia.
2. Kieff E. Epstein-Barr virus and its replication, Fields BN, Knipe DM, Howley PM,. Fields Virology. 1996;2343-2396 Raven, Philadelphia.
3. Baer B, Bankier A, Biggin MD, Deininger P, Farrell PJ, Gibson T, Hudson G, Satchwell S, Seguin C, Tuffnell P, Barrel B. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 310:1984;207-211.
4. Yao Q, Rickinson AB, Epstein M. Oropharyngeal shedding of infectious Epstein-Barr virus in healthy virus immune donors: a prospective study. Chin Med J. 98:1988;191-196.
5. Evans AS, Niederman JC, McCollum RW. Seroepidemiologic studies of infectious mononucleosis with EB virus. N Engl J Med. 279:1968;1121-1127.
6. Ryon JJ, Hayward SD, MacMahon EME, Mann RB, Ling Y, Charache P, Phelan JA, Miller G, Ambinder RF. In situ detection of lytic Epstein-Barr virus infection: Expression of the Not1 early gene and vIL-10 late gene in clinical specimens. J Infect Dis. 168:1993;345-351.
7. Reynolds DJ, Banks PM, Gulley ML. New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease. Am J Pathol. 146:1995;379-388.
8. Klein G, Svedmyr E, Jondal M, Persson PO. EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer. 17:1976;21-26.
9. Laroche C, Drouet EB, Brousset P, Pain C, Boibieux A, Biron F, Icart J, Denoyel GA, Niveleau A. Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas. J Med Virol. 46:1995;66-74.
10. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med. 173:1991;147-158.
11. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells - analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 68:1994;7374-7385.
12. +T cells in acute infectious mononucleosis. Nat Med. 2:1996;906-911.
13. Rickinson AB, Rowe M, Hart IJ, Yao QY, Henderson LE, Rabin H, Epstein MA. T-cell-mediated regression of 'spontaneous' and of Epstein-Barr virus-induced B-cell transformation in vitro: Studies with Cyclosporin A. Cell Immunol. 87:1984;646-658.
14. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer. 35:1985;35-43.
15. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell. 80:1995;593-601.
16. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mannalian cells. Nature. 313:1985;812-815.
17. Rawlins DR, Milman G, Hayward SD, Hayward GS. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell. 42:1985;859-868.
18. Qu L, Rowe DT. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol. 66:1992;3715-3724.
19. Chen F, Zou JZ, di Renzo L, Winberg G, Hu LF, Klein E, Klein G, Ernberg I. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol. 69:1995;3752-3758.
20. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood. 91:1998;1373-1381.
21. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med. 177:1993;339-349.
22. Grasser FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Mueller-Lantzsch N. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood. 84:1994;3792-3798.
23. Niedobitek G, Kremmer E, Herbst H, Whitehead L, Dawson CW, Niedobitek E, von Ostau C, Rooney N, Grasser FA, Young LS. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood. 90:1997;1664-1672.
24. Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood. 86:1995;659-665.
25. Marchini A, Kieff E, Longnecker R. Marker rescue of a transformation-negative Epstein-Barr virus recombinant from an infected Burkitt lymphoma cell line: a method useful for analysis of genes essential for transformation. J Virol. 67:1993;606-609.
26. Kempkes B, Pich D, Zeidler R, Hammerschmidt W. Immortalization of human primary B lymphocytes in vitro with DNA. Proc Natl Acad Sci USA. 92:1995;5875-5879.
27. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature. 340:1989;393-398.
28. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson AB, Kieff E, Cohen JI. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 321:1989;1080-1085.
29. Ambinder RF, Lemas MV, Moore S, Yang J, Fabian D, Krone C. Epstein-Barr virus and lymphoma. Cancer Treat Res. 99:1999;27-45.
30. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. [Review]. Microbiol Rev. 59:1995;387-405.
31. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 15:1997;405-431.
32. Yang, J, Lemas, V, Flinn, I, Krone, C, Ambinder, RF, 1999, Application of the ELISPOT assay to the characterization of CD8 responses to Epstein-Barr virus antigens.
33. Nonkwelo C, Skinner J, Bell A, Rickinson AB, Sample J. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol. 70:1996;623-627.
34. Schaefer BC, Strominger JL, Speck SH. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group 1 Burkitt lymphoma cell lines. Proc Natl Acad Sci USA. 92:1995;10565-10569.
35. Bodescot M, Perricaudet M, Farrell PJ. A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr Virus. J Virol. 61:1987;3424-3430.
36. Jahner D, Stuhlmann H, Stewart CL et al. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature. 298:1982;623-628.
37. Bestor TH, Tycko B. Creation of genomic methylation patterns. Nat Genet. 12:1996;363-367.
38. Bestor TH, Coxon A. The pros and cons of cytosine methylation. Curr Biol. 3:1993;384-386.
39. Reisman D, Sugden B. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol. 6:1986;3838-3846.
40. Sample J, Brooks L, Sample C, Young L, Rowe M, Gregory C, Rickinson AB, Kieff E. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA. 88:1991;6343-6347.
41. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol. 63:1989;2644-2649.
42. Dou S, Zeng X, Cortes P, Erdjument-Bromage H, Tempst P, Honjo T, Vales LD. The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor. Mol Cell Biol. 14:1994;3310-3319.
43. Hsieh JJ, Hayward SD. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science. 268:1995;560-563.
44. Robertson KD, Hayward DJ, Ling PD, Samid D, Ambinder RF. Transcriptional activation of the EBV latency C promoter following 5-azacytidine treatment: Evidence that demethylation at a single CpG site is crucial. Mol Cell Biol. 15:1995;6150-6159.
45. Fuentes-Panana EM, Ling PD. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation. J Virol. 72:1998;693-700.
46. Robertson KD, Ambinder RF. Mapping promoter regions that are hype rsensitive to methylation-mediated inhibition of transcription: Application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. J Virol. 71:1997;6445-6454.
47. Minarovits J, Hu LF, Minarovits-Kormuta S, Klein G, Ernberg I. Se quence-specific methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-promoter regions. Virology. 200:1994;661-667.
48. Altiok E, Minarovits J, Hu LF, Contreras-Brodin B, Klein G, Ernberg I. Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc Natl Acad Sci USA. 89:1992;905-909.
49. Imai S, Koizumi S, Sugiura M et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA. 91:1994;9131-9135.
50. Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood. 88:1996;3129-3136.
51. Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood. 90:1997;4480-4484.
52. Evans TJ, Jacquemin MG, Farrell PJ. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology. 206:1995;866-877.
53. Schaefer BC, Strominger JL, Speck SH. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol. 17:1997;364-377.
54. Masucci MG, Contreras-Salazar B, Ragnar E, Falk K, Minarovits J, Ernberg I, Klein G. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J Virol. 63:1989;3135-3141.
55. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease: application of PCR-based analysis. Am J Pathol. 155:1999;619-625.
56. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylatio n-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:1996;9821-9826.
57. Karlin S, Doerfler W, Cardon LR. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses? J Virol. 68:1994;2889-2897.
58. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol. 72:1998;7075-7083.
59. Ambinder RF, Mann R. Epstein-Barr-encoded RNA in situ hybridization. Hum Pathol. 25:1994;602-605.
60. Minarovits J, Hu LF, Marcsek Z, Minarovits-Kormuta S, Klein G, Ernberg I. RNA polymerase III-transcribed EBER 1 and 2 transcription units are expressed and hypomethylated in the major Epstein-Barr virus-carrying cell types. J Gen Virol. 73:1992;1687-1692.
61. Ambinder RF, Robertson KD, Moore SM, Yang J. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol. 1996;7.
62. Robertson KD, Barletta J, Samid D, Ambinder RF. Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies. Curr Top Microbiol Immunol. 194:1995;145-154.